Corbus Pharmaceuticals (CRBP) PT Lowered to $54 at Oppenheimer

May 13, 2026 8:40 AM

Oppenheimer analyst Jeff Jones lowered the price target on Corbus Pharmaceuticals (NASDAQ: CRBP) to $54.00 (from $57.00) while maintaining a Outperform rating.

No results found